NCT/Study#

2021-0704

Safety of Switching from Intravenous Daratumumab to Subcutaneous Daratumumab in Patients with Multiple Myeloma

Safety of Switching from Intravenous Daratumumab to Subcutaneous Daratumumab in Patients with Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
NA
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: